Review of treatment response in rheumatoid arthritis: assessment of heterogeneity

References

• Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903-11
   PubMed Web of Science ®Google Scholar
• Pisetsky DS, St Clair EW. Progress in the treatment of rheumatoid arthritis. JAMA 2001;286:2787-90
   PubMed Web of Science ®Google Scholar
• Arthritis Foundation. 'Rheumatoid Arthritis'. Available at: www.arthritis.org [Last accessed 30 April 2009]
   Google Scholar
• Van Der Heijde DM, van Riel PL, van Rijswijk MH, et al. Influence of prognostic features on the final outcome in rheumatoid arthritis: a review of the literature. Semin Arthritis Rheum 1988;17:284-92
   PubMed Web of Science ®Google Scholar
• Paimela L, Palosuo T, Leirisalo-Repo M, et al. Prognostic value of quantitative measurement of rheumatoid factor in early rheumatoid arthritis. Br J Rheumatol 1995;34:1146-50
   PubMedGoogle Scholar
• Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81
   PubMed Web of Science ®Google Scholar
• Research Report -- National Center for Complimentary and Alternative Medicine: Rheumatoid Arthritis and Complementary and Alternative Medicine. Available at: http://nccam.nih.gov/health/RA/RA.pdf [Last accessed 8 December 2009]
   Google Scholar
• Sizova L. Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs. Br J Clin Pharmacol 2008;66:173-8
   PubMed Web of Science ®Google Scholar
• Machold KP, Nell VP, Stamm TA, et al. Aspects of early arthritis. Traditional DMARD therapy: is it sufficient? Arthritis Res Ther 2006;8:211
   PubMed Web of Science ®Google Scholar
• van Riel PL, van de Putte LB. DC-ART: what proportion of response constitutes a positive response? J Rheumatol Suppl 1994;41:54-5; discussion 56.:54-5
   PubMedGoogle Scholar
• Ranganath VK, Khanna D, Paulus HE. ACR remission criteria and response criteria. Clin Exp Rheumatol 2006;24:S-21
   PubMed Web of Science ®Google Scholar
• DAS-Score-NL: The home of the DAS. Available at: http://www.das-score.nl/www.das-score.nl/index.html [Last accessed 7 December 2009]
   Google Scholar
• Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005;23:S93-9
   PubMed Web of Science ®Google Scholar
• van Riel PL, van Gestel AM, van de Putte LB. Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers. Br J Rheumatol 1996;35(Suppl 2):4-7
   PubMedGoogle Scholar
• Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q 2004;82:661-87
   PubMed Web of Science ®Google Scholar
• Comparative Effectiveness Review Methods: Clinical Heterogeneity: prepared for AHRQ. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/products/93/533/Clinical_Heterogeneity_Revised_Report_FINAL%;2010-5-10.pdf [Last accessed 1 October 2010]
   Google Scholar
• National Institute for Health and Clinical Excellence (April 2006) 'The guidelines manual'. Available at: www.nice.org.uk [Last accessed 20 October 2008]
   Google Scholar
• Karlsson JA, Kristensen LE, Kapetanovic MC, et al. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008;47:507-13
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Takeuchi T, Inoue E, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). Mod Rheumatol 2008;18:146-52
   PubMed Web of Science ®Google Scholar
• Chehata JC, Hassell AB, Clarke SA, et al. Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity. Rheumatology (Oxford) 2001;40:447-52
   PubMed Web of Science ®Google Scholar
• Rupp I, Boshuizen HC, Roorda LD, et al. Poor and good health outcomes in rheumatoid arthritis: the role of comorbidity. J Rheumatol 2006;33:1488-95
   PubMed Web of Science ®Google Scholar
• Symmons DP. Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol 2002;16:707-22
   PubMed Web of Science ®Google Scholar
• Anderson JJ, Wells G, Verhoeven AC, et al. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22-9
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy. J Rheumatol 2007;34:1674-83
   PubMed Web of Science ®Google Scholar
• Forslind K, Hafstrom I, Ahlmen M, et al. Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis 2007;66:46-52
   PubMed Web of Science ®Google Scholar
• Mottonen T, Paimela L, Leirisalo-Repo M, et al. Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with "sawtooth" strategy. Ann Rheum Dis 1998;57:533-9
   PubMed Web of Science ®Google Scholar
• Fernandez-Nebro A, Irigoyen MV, Urena I, et al. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis. J Rheumatol 2007;34:2334-42
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Watson KD, Silman AJ, et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006;45:1558-65
   PubMed Web of Science ®Google Scholar
• van den Borne BE, Landewe RB, Rietveld JH, et al. Chloroquine therapy in patients with recent-onset rheumatoid arthritis: the clinical response can be predicted by the low level of acute-phase reaction at baseline. Clin Rheumatol 1999;18:369-72
   PubMed Web of Science ®Google Scholar
• Smolen JS, Van Der Heijde DM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006;54:702-10
   PubMed Web of Science ®Google Scholar
• van der HD, Dankert T, Nieman F, et al. Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assessment in rheumatoid arthritis. Rheumatology (Oxford) 1999;38:941-7
   PubMed Web of Science ®Google Scholar
• Buch MH, Seto Y, Bingham SJ, et al. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum 2005;52:42-8
   PubMed Web of Science ®Google Scholar
• Combe B, Cantagrel A, Goupille P, et al. Predictive factors of 5-year health assessment questionnaire disability in early rheumatoid arthritis. J Rheumatol 2003;30:2344-9
   PubMed Web of Science ®Google Scholar
• Maradit-Kremers H, Nicola PJ, et al. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis. J Rheumatol 2006;33:248-55
   PubMed Web of Science ®Google Scholar
• van Roon EN, Hoekstra M, Tobi H, et al. Leflunomide in the treatment of rheumatoid arthritis. An analysis of predictors for treatment continuation. Br J Clin Pharmacol 2005;60:319-25
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Glass RJ, Shadick NA, et al. Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol 2008;35:1737-44
   PubMed Web of Science ®Google Scholar
• Fransen J, Langenegger T, Michel BA, et al. Feasibility and validity of the RADAI, a self-administered rheumatoid arthritis disease activity index. Rheumatology (Oxford) 2000;39:321-7
   PubMed Web of Science ®Google Scholar
• Aletaha D, Funovits J, Keystone EC, et al. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007;56:3226-35
   PubMed Web of Science ®Google Scholar
• Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244-57
   PubMed Web of Science ®Google Scholar
• Sanmarti R, Gomez A, Ercilla G, et al. Radiological progression in early rheumatoid arthritis after DMARDS: a one-year follow-up study in a clinical setting. Rheumatology (Oxford) 2003;42:1044-9
   PubMed Web of Science ®Google Scholar
• Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005;23:S14-18
   PubMed Web of Science ®Google Scholar
• Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45
   PubMed Web of Science ®Google Scholar
• Uhlig T, Smedstad LM, Vaglum P, et al. The course of rheumatoid arthritis and predictors of psychological, physical and radiographic outcome after 5 years of follow-up. Rheumatology (Oxford) 2000;39:732-41
   PubMed Web of Science ®Google Scholar
• Lindqvist E, Saxne T, Geborek P, et al. Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. Ann Rheum Dis 2002;61:1055-9
   PubMed Web of Science ®Google Scholar
• Cohen JD, Dougados M, Goupille P, et al. Health assessment questionnaire score is the best predictor of 5-year quality of life in early rheumatoid arthritis. J Rheumatol 2006;33:1936-41
   PubMed Web of Science ®Google Scholar
• Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol 2007;34:1670-3
   PubMed Web of Science ®Google Scholar
• Matteson EL, Weyand CM, Fulbright JW, et al. How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-year open label trial. Rheumatology (Oxford) 2004;43:619-25
   PubMed Web of Science ®Google Scholar
• Verstappen SM, van Albada-Kuipers GA, Bijlsma JW, et al. A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Ann Rheum Dis 2005;64:38-43
   PubMed Web of Science ®Google Scholar
• Ang DC, Choi H, Kroenke K, et al. Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. J Rheumatol 2005;32:1013-19
   PubMed Web of Science ®Google Scholar
• Jones PW, Ziade MF, Davis MJ, et al. An index of disease activity in rheumatoid arthritis. Stat Med 1993;12:1171-81
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Chang RW, Dwosh I, et al. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502
   PubMed Web of Science ®Google Scholar
• ‘Rheumatoid Arthritis’. Available at: www.niams.nih.gov [Last accessed 27 February 2009]
   Google Scholar
• Kavanaugh A, Klareskog L, van der Heijde D, et al. Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate. Ann Rheum Dis 2008;67:1444-7
   PubMed Web of Science ®Google Scholar